Article: Famotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleFamotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions
AuthorsNg, F2
Wong, S1
Lam, K1
Chu, W2
Chan, P1
Ling, Y2
Kng, C2
Yuen, W2
Lau, Y2
Kwan, A2
Wong, BCY1
Issue Date2010
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
CitationGastroenterology, 2010, v. 138 n. 1, p. 82-88 [How to Cite?]
DOI: http://dx.doi.org/10.1053/j.gastro.2009.09.063
AbstractBackground & Aims: Little is known about the efficacy of H 2-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers. We compared the efficacy of high-dose famotidine with that of pantoprazole in preventing recurrent symptomatic ulcers/erosions. Methods: We performed a randomized, double-blind, controlled trial of 160 patients with aspirin-related peptic ulcers/erosions, with or without a history of bleeding. Patients were given either famotidine (40 mg, morning and evening) or pantoprazole (20 mg in the morning and placebo in the evening). All patients continued to receive aspirin (80 mg daily). The primary end point was recurrent dyspeptic or bleeding ulcers/erosions within 48 weeks. Results: A total of 130 patients (81.1%) completed the study; 13 of 65 patients in the famotidine group reached the primary end point (20.0%; 95% one-sided confidence interval [CI] for the risk difference, 0.1184-1.0) compared with 0 of 65 patients in the pantoprazole group (P < .0001, 95% one-sided CI for the risk difference, 0.1184-1.0). Gastrointestinal bleeding was significantly more common in the famotidine group than the pantoprazole group (7.7% [5/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0226-1.0; P = .0289), as was recurrent dyspepsia caused by ulcers/erosions (12.3% [8/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0560-1.0; P = .0031). No patients had ulcer perforation or obstruction. Conclusions: In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions. © 2010 AGA Institute.
ISSN0016-5085
2011 Impact Factor: 11.675
2011 SCImago Journal Rankings: 1.055
DOIhttp://dx.doi.org/10.1053/j.gastro.2009.09.063
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorNg, F
dc.contributor.authorWong, S
dc.contributor.authorLam, K
dc.contributor.authorChu, W
dc.contributor.authorChan, P
dc.contributor.authorLing, Y
dc.contributor.authorKng, C
dc.contributor.authorYuen, W
dc.contributor.authorLau, Y
dc.contributor.authorKwan, A
dc.contributor.authorWong, BCY
dc.date.accessioned2012-09-05T05:29:38Z
dc.date.available2012-09-05T05:29:38Z
dc.date.issued2010
dc.description.abstractBackground & Aims: Little is known about the efficacy of H 2-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers. We compared the efficacy of high-dose famotidine with that of pantoprazole in preventing recurrent symptomatic ulcers/erosions. Methods: We performed a randomized, double-blind, controlled trial of 160 patients with aspirin-related peptic ulcers/erosions, with or without a history of bleeding. Patients were given either famotidine (40 mg, morning and evening) or pantoprazole (20 mg in the morning and placebo in the evening). All patients continued to receive aspirin (80 mg daily). The primary end point was recurrent dyspeptic or bleeding ulcers/erosions within 48 weeks. Results: A total of 130 patients (81.1%) completed the study; 13 of 65 patients in the famotidine group reached the primary end point (20.0%; 95% one-sided confidence interval [CI] for the risk difference, 0.1184-1.0) compared with 0 of 65 patients in the pantoprazole group (P < .0001, 95% one-sided CI for the risk difference, 0.1184-1.0). Gastrointestinal bleeding was significantly more common in the famotidine group than the pantoprazole group (7.7% [5/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0226-1.0; P = .0289), as was recurrent dyspepsia caused by ulcers/erosions (12.3% [8/65] vs 0% [0/65]; 95% one-sided CI for the risk difference, 0.0560-1.0; P = .0031). No patients had ulcer perforation or obstruction. Conclusions: In patients with aspirin-related peptic ulcers/erosions, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions. © 2010 AGA Institute.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationGastroenterology, 2010, v. 138 n. 1, p. 82-88 [How to Cite?]
DOI: http://dx.doi.org/10.1053/j.gastro.2009.09.063
dc.identifier.doihttp://dx.doi.org/10.1053/j.gastro.2009.09.063
dc.identifier.epage88
dc.identifier.issn0016-5085
2011 Impact Factor: 11.675
2011 SCImago Journal Rankings: 1.055
dc.identifier.issue1
dc.identifier.pmid19837071
dc.identifier.scopuseid_2-s2.0-72249102783
dc.identifier.spage82
dc.identifier.urihttp://hdl.handle.net/10722/163286
dc.identifier.volume138
dc.languageeng
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
dc.publisher.placeUnited States
dc.relation.ispartofGastroenterology
dc.relation.referencesReferences in Scopus
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazoles - Administration & Dosage
dc.subject.meshAged
dc.subject.meshAnti-Bacterial Agents - Therapeutic Use
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Adverse Effects
dc.subject.meshAnti-Ulcer Agents - Administration & Dosage
dc.subject.meshAspirin - Adverse Effects
dc.subject.meshFamotidine - Administration & Dosage
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshGastrointestinal Hemorrhage - Chemically Induced - Epidemiology - Prevention & Control
dc.subject.meshHelicobacter Infections - Drug Therapy - Epidemiology
dc.subject.meshHistamine H2 Antagonists - Administration & Dosage
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPeptic Ulcer - Chemically Induced - Epidemiology - Prevention & Control
dc.subject.meshRecurrence - Prevention & Control
dc.subject.meshRisk Factors
dc.subject.meshTreatment Outcome
dc.titleFamotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Ruttonjee Hospital Hong Kong